Cullinan Oncology
Stock Forecast, Prediction & Price Target
Cullinan Oncology (CGEM) stock Price Target by analysts
$30
Potential upside: 299.46%
Cullinan Oncology price prediction
What is Cullinan Oncology stock analysts` prediction?
Cullinan Oncology stock forecast: Based on 1 Wall Street analysts` predicted price targets for Cullinan Oncology in the last 3 months, the avarage price target is $30, with a high forecast of $NaN. The average price target represents a 299.46% change from the last price of $7.51.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Cullinan Oncology stock Price Target by analysts
Full breakdown of analysts given Cullinan Oncology price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Dai UBS | 0% 0/1 | 11 months ago | $30 299.46% upside | $15.61 | StreetInsider | Previous targets (0) |
Jeffrey Hung Morgan Stanley | 0% 0/1 | about 1 year ago | $38 405.99% upside | $16.38 | StreetInsider | Previous targets (0) |
Edward White H.C. Wainwright | 0% 0/2 | over 1 year ago | $28 272.83% upside | $26.72 | TheFly | Previous targets (1) |
Kaveri Pohlman BTIG | 0% 0/1 | over 1 year ago | $30 299.46% upside | $17.32 | StreetInsider | Previous targets (0) |
Edward White H.C. Wainwright | 0% 0/2 | over 1 year ago | $29 286.15% upside | $17.63 | TheFly | Previous targets (1) |
Unknown Morgan Stanley | N/A | over 2 years ago | $19 152.99% upside | $11.91 | Benzinga | N/A |
Cullinan Oncology Financial Estimates
Cullinan Oncology Revenue Estimates
Cullinan Oncology EBITDA Estimates
Cullinan Oncology Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.94M N/A | $0 -100% | $0 0% | Avg: $11.59M Low: $10.91M High: $12.26M avg. 0% | Avg: $29.41M Low: $28.08M High: $30.74M avg. 153.76% | Avg: $63.55M Low: $60.68M High: $66.42M avg. 116.06% | Avg: $54.81M Low: $52.33M High: $57.28M avg. -13.75% |
Net Income
% change YoY
| $-65.04M N/A | $111.21M 270.99% | $-153.16M -237.71% | Avg: $-188.93M Low: $-174.92M High: $-92.65M avg. -23.35% | Avg: $-192.49M Low: $-197.36M High: $-98.05M avg. -1.88% | Avg: $-98.05M Low: $-103.80M High: $-92.29M avg. 49.05% | Avg: $-113.18M Low: $-119.81M High: $-106.52M avg. -15.42% |
EBITDA
% change YoY
| $-67.95M N/A | $-408.92M -501.76% | $-190.33M 53.45% | Avg: $6.95M Low: $6.54M High: $7.36M avg. 103.65% | Avg: $17.65M Low: $16.85M High: $18.44M avg. 153.76% | Avg: $38.13M Low: $36.41M High: $39.85M avg. 116.06% | Avg: $32.88M Low: $31.40M High: $34.37M avg. -13.75% |
EPS
% change YoY
| -$1.47 N/A | $2.46 267.34% | -$3.69 -250% | Avg: -$3.09 Low: -$4.21 High: -$2.23 avg. 16.15% | Avg: -$3.02 Low: -$4.75 High: -$2.36 avg. 2.52% | Avg: -$2.36 Low: -$2.5 High: -$2.22 avg. 21.74% | Avg: -$2.72 Low: -$2.88 High: -$2.56 avg. -15.42% |
Operating Expenses
% change YoY
| $86.89M N/A | $132.13M 52.06% | $191.08M 44.61% | Avg: $12.84M Low: $12.08M High: $13.59M avg. -93.28% | Avg: $32.58M Low: $31.11M High: $34.05M avg. 153.76% | Avg: $70.40M Low: $67.22M High: $73.57M avg. 116.06% | Avg: $60.71M Low: $57.97M High: $63.45M avg. -13.75% |
FAQ
What is Cullinan Oncology stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 2.09% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -174.92M, average is -188.93M and high is -92.65M.
What is Cullinan Oncology stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 64.01% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $10.91M, average is $11.59M and high is $12.26M.
What is Cullinan Oncology stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 6.25% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$4.21, average is -$3.09 and high is $-2.23.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Cullinan Oncology stock. The most successful analyst is David Dai.